Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
382,523,969
-
Total 13F shares
-
697,065,726
-
Share change
-
+97,782,865
-
Total reported value
-
$1,656,209,842
-
Put/Call ratio
-
46%
-
Price per share
-
$2.38
-
Number of holders
-
239
-
Value change
-
+$215,498,097
-
Number of buys
-
163
-
Number of sells
-
64
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q2 2022
As of 30 Jun 2022 RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) had 239 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 697,065,726 shares of stock of the company.
Largest 10 holders included BAILLIE GIFFORD & CO, VANGUARD GROUP INC, GENERAL ATLANTIC, L.P., Anchorage Capital Group, L.L.C., MORGAN STANLEY, BlackRock Inc., VIKING GLOBAL INVESTORS LP, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., and STATE STREET CORP.
This table shows 242 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.